
    
      In this study the investigators will prospectively investigate pulmonary adverse events
      during treatment with everolimus. The investigators will distinguish the following
      everolimus-induced pulmonary adverse events: pulmonary infection, everolimus-induced airway
      disease and everolimus-induced interstitial lung disease (ILD). The investigators will
      investigate the predictive value of pneumoproteins, everolimus exposure, pulmonary function
      tests, four distinct radiological patterns, baseline patient characteristics and the
      development of skin toxicity or oral mucositis for the development and severity of
      everolimus-induced ILD.
    
  